Cell Line Characterization and Cell Line Development Market

Cell Line Characterization and Cell Line Development Market (3rd Edition), Industry Trends and Forecasts till 2035: Distribution by Source of Cell Line / Expression System (Mammalian, Microbial, Insect and Others), Application of Cell Line (Research and Development, and Biomanufacturing), Company Size (Small, Mid-Sized, Large) and Key Geographical Regions (North America, Europe, Asia Pacific and Rest of the World): Industry Trends and Global Forecasts

  • Lowest Price Guaranteed From USD 4,799

  • Companies Covered
    617

  • Pages
    455

  • View Count
    20747

Cell Line Characterization and Cell Line Development Market Overview

The global cell line development and characterization market size is estimated to grow from USD 2.29 billion in 2024 to USD 8.38 billion by 2035, representing a CAGR of 12.5% during the forecast period 2024-2035.

Cell Line Characterization and Cell Line Development Market, By Type of Service, 2024-2035 (USD Billion)

To learn more about this report, request a free sample copy

The new research study consists of industry trends, detailed market analysis, key market insights, market impact analysis, and market forecast and opportunity analysis. The growth in the cell line characterization and cell line development market size over the next decade is likely to be the result of anticipated increase in adoption of biologics and growing preference for outsourcing.

Over the years, the growing promise of biopharmaceuticals (for the treatment of hard-to-treat indications, including immunological, oncological and rare disorders) and advent of novel technologies for the development of ground-breaking biological treatments has piqued the interest of several industry and academic stakeholders. Currently, more than 200 biologics are commercially available and over 10,000 candidates are under clinical evaluation. Further, the development and manufacturing of biologics requires living biological systems / cell lines. Cell lines are a group of cells that are derived from a single cell and are cultured using appropriate growth medium in laboratories. Notably, there has been a surge in demand for different types of cell lines (including mammalian (human cell lines and non-human cell lines), microbial, insect, marine and avian cell lines). Currently, around 70% of the total recombinant protein therapeutics are produced using Chinese Hamster Ovary cells (CHO cells).

Cell line development and cell line authentication is a cost-intensive and complex process that requires multidisciplinary expertise. In fact, considering their critical role in drug discovery and development, cell lines need to be appropriately tested and validated; this further prevents misidentification of cell lines, detects presence of contaminants / harmful microorganisms, monitors genetic stability and ensures authenticity of the experimental research. Consequently, drug developers are increasingly relying on service providers with specialized equipment and expertise to deal with the technical and operational challenges (including gene expression fluctuation and cell line impurities). Further, contracting a service provider enables drug developers / sponsors to leverage innovative and advanced technologies (available with the service provider) and achieve greater operational flexibility. With the rising demand for novel biologics (including cell therapies, gene therapies monoclonal antibodies, recombinant proteins and vaccines), ongoing advancements in the technologies and growing preference for outsourcing, the market for cell line development and cell line characterization service providers is likely to grow, in the foreseen future.

Market Share Insight

The cell line characterization and cell line development report present an in-depth analysis of the various companies that are engaged in the global cell line development and cell line characterization service industry, across different segments, as defined in the table below:

Cell Line Characterization and Cell Line Development: Market Outlook / Report Segmentations

Key Data Points Report Insights

Historical Trend

2019-2022

Base Year

2022

Forecast Period

2023-2035

Cell Line Development Market Size 2023

$1,014 Million

Cell Line Development CAGR

13.2%

Cell Line Characterization Market Size 2023

$ 871 Million

Cell Line Characterization CAGR

13.3%

Source of Cell Lines / Expression System
  • Mammalian
  • Microbial
  • Insect
  • Others
Application of Cell Lines
  • Research and Development
  • Drug Development
Company Size
  • Very Large and Large
  • Mid-sized
  • Small
Key Geographical Regions
  • North America
  • Europe
  • Asia Pacific and Rest of the World
Key Companies Profiled
  • ATUM
  • ATZ Labs (a subsidiary of Life Technologies)
  • Avance Biosciences
  • BioReliance (acquired by Sigma-Aldrich)
  • Biovian
  • Celonic Group
  • Charles River Laboratories
  • ChemPartner
  • Cleancells
  • Creative Biogene
  • Curia
  • Eurofins BioPharma Product Testing
  • FUJIFILM Diosynth Biotechnologies
  • Hylabs
  • KBI Biopharma
  • Kemp Proteins
  • KMD Bioscience
  • Livogen Pharmed
  • Lonza
  • Molecular Diagnostic Services
  • Mycenax Biotech
  • ProBioGen
  • Samsung BioLogics
  • Sartorius
  • SGS Life Sciences
  • Syngene International
  • Texcell
  • TFBS Bioscience
  • Thermo Fisher Scientific
  • WuXi Advanced Therapies
  • WuXi Biologics
(Full list of 350+ companies and organizations captured is available in the report)
PowerPoint Presentation (Complimentary)

Available

Customization Scope

15% Free Customization

Excel Data Packs (Complimentary)
  • Market Landscape (Cell Line Development)
  • Market Landscape (Cell Line Characterization)
  • Company Competitiveness Analysis (Cell Line Development)
  • Company Competitiveness Analysis (Cell Line Characterization)
  • Partnerships and Collaborations
  • Recent Expansions
  • Market Forecast and Opportunity Analysis (Cell Line Development)
  • Market Forecast and Opportunity Analysis (Cell Line Characterization)


One of the key objectives of this market report was to estimate the current market size, opportunity and the future growth potential of the cell line characterization and cell line development market, over the forecast period. Based on multiple parameters, likely adoption trends and through primary validations, we have provided an informed estimate on the market evolution during the forecast period 2023-2035. The market report also features the likely distribution of the current and forecasted opportunity within the cell line characterization and cell line development market across various segments, such as source of cell line (mammalian, microbial, insect and others), application of cell line (research and development, and drug development), company size (small, mid-sized, large) and key geographical regions (North America, Europe, Asia Pacific and rest of the world). In order to account for future uncertainties associated with some of the key parameters and to add robustness to our model, we have provided three market forecast scenarios, namely conservative, base, and optimistic scenarios, representing different tracks of the industry’s evolution.

CLDC Services Market Key Geographical Regions

The opinions and insights presented in the market report were influenced by discussions held with stakeholders in the industry. The report features detailed transcripts of interviews held with the following industry stakeholders:

  • Chief Executive Officer, Small Company, UK
  • Principal Scientist and Head, R&D, Mid-size Company, India
  • Director, Business Development and Marketing, Mid-size Company, France
  • Founder and Managing Director, Small Company, Germany
  • Chief Executive Officer, Mid-sized Company, China
  • Former Chief Scientific Officer, Large Company, Poland
  • Director of Business Development and Marketing, Mid-Sized Company, France
  • Director of Client Relations, Mid-Sized Company, US
  • President, Small Company, US
  • Former Vice President Bioprocessing, Very Large Company, US
  • Former Global Business Development Manager, Large Company, Poland

Further, all actual figures have been sourced and analyzed from publicly available information forums and primary research discussions. Financial figures mentioned in this market report are in USD, unless otherwise specified.

Overview of Key Segments

Market Share by Source of Cell Lines

The global cell line characterization and cell line development market is categorized based on different source of cell lines, such as mammalian, microbial, insect and other cell lines. The mammalian cell line segment occupies the highest share in 2023 (in both the development and characterization forecast) and is expected to witness substantial growth in the coming years. 

Market Share by Application of Cell Line

The global cell line characterization and cell line development market is segmented into bioproduction and research and development operations. Among these segments, it has been observed that majority share of the cell line development market is currently captured by cell lines developed for bioproduction. This can be attributed to the fact that the rising incidence of chronic diseases has led to the need for developing high-quality biologics, such as monoclonal antibodies and recombinant proteins.

Market Share by Geography

This segment highlights the distribution of cell line characterization and cell line development market across various geographies, such as North America, Europe, and Asia-Pacific and rest of the world regions. According to our projections, the cell line development market in North America is likely to capture majority (41%) of the overall market share, and this trend is unlikely to change in the future. In addition, in cell line characterization market, Asia-pacific and rest of the world is expected to grow at a relatively healthy CAGR (12.1%), during the forecast period, 2023-2035.

Key Market Insights

The Cell Line Characterization and Cell Line Development Market (3rd Edition), 2019-2022 (Historical Trends) and 2023-2035 (Forecasted Estimates): Distribution by Source of Cell Line / Expression System (Mammalian, Microbial, Insect and Others), Application of Cell Line (Research and Development, and Drug Development), Company Size (Small, Mid-Sized, Large) and Key Geographical Regions (North America, Europe, Asia Pacific and Rest of the World): Industry Trends and Global Forecasts report features an extensive study of the current market landscape, market size and future opportunities within the cell line characterization and cell line development industry, during the given forecast period. The market report highlights the efforts of several stakeholders engaged in this rapidly emerging market segment of the pharmaceutical industry. Key takeaways of the cell line characterization and cell line development market report are briefly discussed below.

Competitive Landscape of Cell Line Development Companies

The current market landscape features the presence of close to 210 cell line development service providers, spread across the globe. Overall, the market seems to be well-fragmented, featuring the presence of very large, large, mid-sized and small companies, which have the required expertise to offer mammalian cell line development (cho cell line development, HEK cell line development) and non-mammalian cell line development services. Further, 45% of the service providers offer stable cell line development. Majority (96%) of cell line development companies offer cell lines for development of recombinant cells, followed by companies that offer hybridoma cells (27%) and primary cell line (26%). It is important to mention that over 35% companies use serum free / animal component free media for cell culturing; notable examples include (alphabetical order) ABclonal, EirGenix, Profacgen, Sino Biological and Vista Biologicals.

Examples of key cell line development companies include (which have been profiled in the report, alphabetical order) ATUM, Biovian, Celonic Group, ChemPartner, Creative Biogene, Curia, FUJIFILM Diosynth Biotechnologies, KBI Biopharma, Kemp Proteins, KMD Bioscience, Lonza, Mycenax Biotech, ProBioGen, Syngene International, Thermo Fisher Scientific and WuXi Biologics.

CLDC Services Market Types of Characterization

Competitive Landscape of Cell Line Characterization Service Providers 

The current market landscape features the presence of over 140 industry players involved in offering cell line characterization and cell line validation services. Majority (85%) of the players offer identity / stability testing services for cell lines; of these, around 70% offer genotyping analysis using DNA fingerprinting / short tandem repeat profiling (str testing), followed by next generation sequencing (NGS) (34%) and copy number variation (CNV) analysis  (33%). Further, it is worth noting that close to 30% of the industry players offer cell line development along with cell line authentication services. 

Examples of prominent players offering cell line characterization services include (which have been profiled in the market report, in alphabetical order) ATZ Labs, Avance Biosciences, BioReliance, Charles River Laboratories, Cleancells, Eurofins BioPharma Product Testing, Hylabs, Livogen Pharmed, Molecular Diagnostic Services, Samsung BioLogics, Sartorius, SGS Life Sciences, Texcell, TFBS Bioscience and WuXi Advanced Therapies

Additionally, close to 60 non-industry players are involved in offering cell line validation and cell line authentication services. Over 55% of these players are based in North America, followed by Europe (24%) and Asia-Pacific (20%). In addition, majority (55%) of the organizations use GenePrint 10 System for performing genotyping analysis; examples include (alphabetical order) Case Western Reserve University, Dana Farber Cancer Institute, The Centre for Applied Genomics, University of California, University of Pennsylvania, University of Utah, UT Southwestern Medical Center and Yale School of Medicine. 

Market Trends: Partnerships and Collaborations on the Rise for Cell Line Development and Characterization

In recent years, several partnerships have been established by industry stakeholders, in order to enhance their capabilities and consolidate their presence in the cell line development and characterization domain. It is worth highlighting that over 35% of these partnerships have been established in the past two years. For instance, in June 2023, Synthego signed an agreement with American Type Culture Collection (ATCC) to combine the former company’s CRISPR gene-editing expertise with the latter company’s mammalian and mouse cell lines. Interestingly, most of the agreements were licensing agreements, followed by product development and manufacturing agreements, and mergers and acquisitions. Such partnerships will further support biotechnology research and accelerate the drug discovery process, thereby enabling the drug developers to meet the growing demand of novel therapeutics (such as biologics and biosimilars). Additionally, this increased demand will further drive the market growth for cell line characterization and cell line development services during the forecast period of this market report.

Expansion of Facilities to Enhance Cell Line Development and Cell line Characterization Capabilities

A number of service providers have taken initiatives to expand their existing facilities and incorporate advanced technologies to meet the growing demand for cell line development, cell line testing and cell line profiling services, reduce cost of operation and comply to the evolving safety and regulatory requirements. Notably, more than 55% of the expansion initiatives undertaken in this domain were reported in 2022 and 2023. In July 2023, Charles River Laboratories, a US-based Contract Development and Manufacturing Organization (CDMO), expanded its analytical testing laboratory in County Mayo, Ireland. With investment of EUR 10 million, the expansion is focused on enhancing the company’s testing capabilities for novel cell and gene therapies, and mRNA platform therapies. Driven by the growing need for high quality cell lines and demands of clients in this domain, we anticipate the service providers to continue to expand their facilities and strengthen their capabilities.

CLDC Services Market, Recent Expansions

Market Analysis: Global Cell line Development Market Size

The global cell line development market is estimated to be worth USD 1,014 million in 2023. Further, driven by the rise in incidence of chronic diseases, growing demand for biologics and biosimilars, and the ongoing advancements in the cell line development technologies, the cell line development market is anticipated to grow at a CAGR of 13.2% during the forecast period. In terms of sources of cell lines / expression systems, the mammalian cell line will drive the market growth for cell line development services. 

Regional Analysis: North America to Hold the Largest Share in Cell Line Development Market

Majority of the companies offering cell line development services are headquartered in North America, followed by companies based in Europe. Therefore, close to 45% of the global market for cell line development services market is anticipated to be captured by companies based in North America, by 2035. 

Cell Line Characterization Services Market Size: Bioproduction Segment Holds the Largest Market Share

The global cell line characterization market is estimated to be worth USD 871 million in 2023. Driven by the rising need for high quality and authentic cell lines for experimental research, the opportunity for cell line testing service providers is anticipated to grow at a CAGR of 13.3% during the forecast period. Further, the overall cell line characterization market for bioproduction is anticipated to capture 74% share.

Market Drivers: Technological Advancement in Cell Line Authentication and Cell Line Development Industry

The conventional cell line development process is plagued with certain challenges, including high turnaround time, labor-intensive workflow, batch-to-batch variability and requirement of strict regulatory compliance. In order to mitigate the unforeseen and other prevailing challenges, the industry has shifted towards automated cell line development process. New genome editing technologies, such as the CRISPR/Cas-9, are being extensively used to improve the quality of recombinant cell lines. In June 2023, Thermo Fisher Scientific entered into an agreement with Celltrio to integrate the latter company’s RoboCell cell line automation platform with the former company’s cell line workflow software; the partnership presently aims to address the unmet need for high-throughput automated cell line development in Europe. Further, automated high throughput systems enable rapid screening of large numbers of cell lines / cultures simultaneously. The induced pluripotent stem cell (iPSC) technology has also enabled the development of patient-specific cell lines for tissue engineering and personalized regenerative medicine.

CLDC Services Market Distribution by Company Size

Report Coverage

The cell line characterization and cell line development market report presents an in-depth analysis, highlighting the capabilities of various service providers engaged in this market, across different segments. Amongst other elements, the market report includes:

  • A preface providing an introduction to the full report, Cell Line Characterization and Cell Line Development Market (3rd Edition), 2019-2022 (Historical Trends) and 2023-2035 (Forecasted Estimates).
  • An outline of the systematic research methodology adopted to conduct the study on cell line characterization and cell line development services, providing insights on the various assumptions, methodologies, and quality control measures employed to ensure accuracy and reliability of our findings.
  • An overview of economic factors that impact the overall cell line characterization and cell line development industry, including historical trends, currency fluctuation, foreign exchange impact, recession, and inflation measurement.
  • An executive summary of the insights captured during our research. It offers a high-level view on the current state of cell line characterization and cell line development market and its likely evolution in the mid-long term.
  • A general overview of cell cultures and its different types (based on origin and growth properties). The chapter also provides information on cell lines, highlighting its different types (based on lifespan of cell line, type of cell line (finite cell lines and continuous cell lines) and source of cell line (human cell line, non-human mammalian cell line and other cell lines)) and applications. It also outlines the general concepts of cell line characterization along with a detailed description of different testing methods. Further, the chapter discusses the challenges associated with cell lines, as well as the growing need for outsourcing cell line development and characterization operations.
  • A detailed assessment of cell line development service providers, based on several relevant parameters, including year of establishment, company size (in terms of employee count), location of headquarters (North America, Europe and Asia Pacific), source of cell lines / expression systems offered (mammalian, microbial, insect and others), gene delivery method used (biological, chemical and physical), type of transfection (stable transfection and transient transfection), availability of serum free / animal component free culturing capability, type of cells offered (primary, hybridoma and recombinant), application of cell lines (research and development, biologics production, diagnostics and tissue engineering / cell therapy), additional cell line related services offered (cell banking, cell bank characterization, process development, quality testing / control, manufacturing, fill / finish), type of cell banking (Master Cell Bank (MCB), Research Cell Bank (RCB), Working Cell Bank (WCB) and End of Production Cell (EoP)) and availability of integrated cell line characterization. Further, the chapter also provides information on the technology platform utilized, monoclonality procedure used, availability of biosimilar cell line development and gene editing cell line development services.
  • An insightful competitiveness analysis of cell line development service providers based on supplier strength (in terms of years of experience and company size), and service strength (in terms of sources of cell lines and expression systems handled, type of gene delivery methods used, type of transfection done, application of cell lines and additional cell line related services offered).
  • Elaborate profiles of leading companies (shortlisted based on the scores of competitiveness analysis) engaged in offering cell line development services. Each profile features a brief overview of the company (including information on year of establishment, location of headquarters, number of employees, leadership team and financial information (if available)), details related to its cell line development service portfolio, recent developments and an informed future outlook. In addition to the leading service providers for cell line development, some other prominent players have also been profiled, for which information on company overview and cell line development service portfolio has been provided.
  • A detailed assessment of the companies / organizations providing cell line characterization services, based on several relevant parameters, including year of establishment, company size (in terms of employee count), location of headquarters (North America, Europe and Asia Pacific), source of cell lines and expression systems offered (mammalian, microbial, insect and others), type of cell line characterization services offered (cell identity testing / cell stability testing, sterility / biosafety testing, expression testing and oncogenicity / tumorigenicity testing), type of cell identity testing / cell stability testing services offered (Karyotyping Analysis (Hybridization Testing and Chromosome Banding), Genotyping Analysis (DNA Fingerprinting / STR Analysis, CNV Analysis, NGS, Polymerase Chain Reaction (PCR), Southern Blotting and DNA Barcoding (CO1 Barcode Assay) and others (analysis of cell morphology, viability testing and isozyme analysis), type of sterility / biosafety testing services offered (mycoplasma contamination testing, microbial contamination testing and viral contamination testing), availability of additional cell line related services (cell line development, cell banking and mycoplasma clearance testing), regulatory accreditations / certifications and overall turnaround time. For non-industry players, the chapter provides additional information on number of STR loci amplified, type of genotyping kit used, and service fee charged.
  • An insightful competitiveness analysis of cell line characterization service providers based on supplier strength (in terms of years of experience and company size), and service strength (in terms of number of cell lines characterized, number of types of cell line identity / stability testing services offered, number of types of cell line sterility / biosafety testing services offered, availability of expression testing service, availability of oncogenicity / tumorigenicity testing and number of additional cell line related services offered).
  • Elaborate profiles of prominent companies (shortlisted based on the scores of competitiveness analysis) engaged in offering cell line characterization services. Each profile features a brief overview of the company (including information on year of establishment, location of headquarters, number of employees, leadership team and financial information (if available)), details related to its cell line characterization service portfolio, recent developments and an informed future outlook. In addition to the leading service providers for cell line characterization, some other prominent players have also been profiled, for which information on company overview and cell line development service portfolio has been provided.
  • A detailed analysis of the partnerships inked between stakeholders engaged in this industry, during the period 2015-2023 (till September), based on several parameters, such as year of partnership, type of partnership, type of cells involved, therapeutic area, type of partner and most active players (in terms of the number of partnerships signed). It also provides the regional distribution of the companies involved in these agreements.
  • A detailed analysis of the recent expansions undertaken by various cell line development and cell line characterization service providers, based on various relevant parameters, such as year of expansion, type of expansion, location of headquarters, location of expanded facility, area of expanded facility, purpose of expansion, most active players (in terms of number of recent expansions) and geographical distribution.
  • Detailed profiles of the biorepositories across the globe that play an important role in developing cell lines and have also undertaken initiatives to limit the use of contaminated and / or misidentified cell lines. Each profile features a brief overview of the repository and its cell line characterization service portfolio. 
  • An elaborate discussion on the requirements established by various regulatory authorities, across different regions, related to characterization of cell lines. In addition, it provides insights from the various guideline documents that have been issued by these bodies on protocols that need to be followed and general tips for the testing of cell lines. It also features a brief historical overview and discussion on the contributions of key institutes / organizations involved in this domain.
  • An in-depth analysis of the factors that can impact the growth of cell line development and characterization market. It also features identification and analysis of key drivers, potential restraints, emerging opportunities, and existing challenges.
  • A detailed market forecast analysis in order to estimate the existing market size and future opportunity for cell line development market over the next decade. Based on multiple parameters, such as likely adoption trends and through primary validations, we have provided an informed estimate on the market evolution during the forecast period 2023-2035. The report also features the likely distribution of the current and forecasted opportunity within the cell line development market. Further, in order to account for future uncertainties and to add robustness to our model, we have provided three forecast scenarios, namely conservative, base and optimistic scenarios, representing different tracks of the industry’s growth.
  • Detailed projections of the current and future cell line development market across different sources of cell lines / expression systems such as mammalian, microbial, insect and others.
  • Detailed projections of the current and future cell line development market across different applications of cell lines such as research and development purposes, and bioproduction.
  • Detailed projections of the current and future cell line development market across different company sizes, such as very large and large companies, mid-sized companies and small companies.
  • Detailed projections of the current and future cell line development market across various geographies, such as North America, Europe, asia pacific and rest of the world.
  • Detailed market forecast analysis in order to estimate the existing market size and future opportunity for cell line characterization market over the next decade. Based on multiple parameters, such as likely adoption trends and through primary validations, we have provided an informed estimate on the market evolution during the forecast period 2023-2035. The report also features the likely distribution of the current and forecasted opportunity within the cell line characterization market. Further, in order to account for future uncertainties and to add robustness to our model, we have provided three forecast scenarios, namely conservative, base and optimistic scenarios, representing different tracks of the industry’s growth.
  • Detailed projections of the current and future cell line development market across different sources of cell lines / expression systems such as mammalian, microbial, insect and others.
  • Detailed projections of the current and future cell line development market across different applications of cell lines such as research and development purposes, and bioproduction.
  • Detailed projections of the current and future cell line development market across different company sizes, such as very large and large companies, mid-sized companies and small companies.
  • Detailed projections of the current and future cell line development market across various geographies, such as North America, Europe, asia pacific and rest of the world.

Recent Developments in Cell Line Testing and Cell Line Development Market

Several recent developments have taken place in the cell line characterization and cell line development industry, some of which have been outlined below. These developments, even though took place post the release of our market report, substantiate the overall market trends that we have outlined in our analyses.

  • In September 2023, Lineage Cell Therapeutics (in collaboration with Eterna Therapeutics), announced the initiation of the development of engineered hypoimmune pluripotent cell lines to treat neurological indications.
  • In September 2023, 3P Biopharmaceuticals, a Spain-based CDMO, announced the opening of  its new 1,400 sq. m analytical laboratories to expand its cell line characterization capacity.
  • In June 2023, Matica Bio launched MatiMax  HEK293 and HEK293T cell lines to advance the development of cell and gene therapies; these cell lines enhance the doubling times, improve the transfection efficiencies and increase the production capacity.
  • In June 2023, KBI Biopharma (a JSR Life Sciences company) launched a microbial cell line development platform, KBI PUREplatform ; through the platform, the company aims to enhance efficiencies of the microbial expression landscape for biopharmaceutical production and create new market opportunities.
  • In June 2023, Curia signed a licensing agreement with MilliporeSigma to use the latter company’s CHOZN GS cell line technology to manufacture therapeutic proteins and antibodies.

Author(s): Simran Kaur, Hardik Patel

Frequently Asked Questions

Question 1: What is a cell line?

Answer: Cell line refers to a defined population of cells (derived from a single cell) that can be cultured using an appropriate growth medium in laboratory conditions.

Question 2: What is cell line designation?

Answer: Cell line designation refers to the unique code or designation given to a cell line for its identification. For instance, cell line number NHB2-1 indicates that the cell line is from a normal human brain.

Question 3: What is the most popular cell line?

Answer: Mammalian cell cultures have gained significant traction in the scientific domain, owing to their ability to produce large, complex proteins with correct post-translational modifications (similar to the ones found in humans). Some commonly used mammalian cell lines include baby hamster kidney (BHK 21) cell lines, cho cells and murine myeloma cell lines (NS0 and Sp2/0).

Question 4: What is the cell line development process? How is a cell line created?

Answer: Cell line development is the process of developing cell lines (through isolation, culturing, cloning and genetic modification) to advance the scientific understanding and development of novel therapeutic modalities.

Question 5: What is cell line development used for?

Answer: Cell lines serve as powerful and versatile tool, fueling breakthroughs in biomedical research and drug discovery. They are used to study various cellular processes, understand the biology of diseases, produce biopharmaceuticals (such as enzymes, growth factors, monoclonal antibodies, recombinant protein, gene therapies and vaccines), and determine the efficacy and safety of potential drug candidates.

Question 6: What is cell line characterization?

Answer: Cell line characterization refers to the process of evaluating the identity, functionality, stability and purity of cell lines.

Question 7: What are the two methods of cell line characterization?

Answer: The two primary methods of cell line characterization include cell line identity / stability testing (involving copy number variation analysis, DNA barcoding (CO1 barcode assay), DNA fingerprinting / STR analysis and isozyme analysis) and cell line sterility testing (involving mycoplasma contamination testing, microbial contamination testing and viral contamination testing). Some other methods include expression testing and oncogenicity / tumorigenicity testing.

Question 8: How big is the cell line development market?

Answer: The cell line development market size is anticipated to be worth USD 1,014 million in 2023 and is expected to grow at a CAGR of 13.2% during the forecast period 2023 to 2035.

Question 9: What is the likely market size for cell line characterization market?

Answer: The cell line characterization market size is anticipated to be worth USD 871 million in 2023 and USD 3,879 million in 2035.

PRICING DETAILS

This license grants the right of use of the purchased report to a single recipient only (normally the person who buys the report). You may access the material on your computer, as and when required, for your own personal use. You may also print Read more about Single-User License

This license grants the right of use of the purchased report by the employees of a business unit at a particular site/office location. The report may be accessed on the computer of any employee within the business unit. You may also print multiple Read more about One Location Site License

This license grants the right of use of the purchased report by a department / team of individuals (up to 12) in a particular organization. The license does not limit the use to a particular site / office location. The report may be accessed on the computer Read more about Department License

This license entitles the buyer of the report to share, distribute the report (either full or in part) with other employees of the same firm/enterprise. The report may be accessed by any employee of the enterprise and there is no limit on the Read more about Enterprise License

Discounts available for multiple report purchases
Click here to send an email to Roots Analysis team. sales@rootsanalysis.com